Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Cancer Therapies02:49

Cancer Therapies

9.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

401
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
401
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A young gas giant and hidden substructures in a protoplanetary disk.

Nature astronomy·2025
Same author

Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical Trial.

JAMA surgery·2025
Same author

Novel Postneoadjuvant Prognostic Breast Cancer Staging System.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Probing iron in Earth's core with molecular-spin dynamics.

Proceedings of the National Academy of Sciences of the United States of America·2024
Same author

Impact of Affordable Care Act Provisions on the Racial Makeup of Patients Enrolled at a Deep South, High-Risk Breast Cancer Clinic.

Journal of racial and ethnic health disparities·2024
Same author

Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024

Related Experiment Video

Updated: Dec 2, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K

Less Toxic Chemotherapy in Locally Advanced Breast Cancer.

John Carpenter1, Andres Forero1, Carla I Falkson1

  • 1From the Division of Hematology/Oncology, the Department of Radiation Oncology, the Department of Surgery, the Division of Preventive Medicine, and the UAB Comprehensive Cancer, University of Alabama at Birmingham, Birmingham.

Southern Medical Journal
|November 3, 2020
PubMed
Summary
This summary is machine-generated.

This study shows a less toxic preoperative chemotherapy regimen for locally advanced breast cancer, achieving significant tumor reduction and pathological complete responses (pCRs) with minimal side effects. Long-term outcomes demonstrate sustained recurrence-free survival and overall survival.

More Related Videos

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

4.8K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.3K

Related Experiment Videos

Last Updated: Dec 2, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K
Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
13:43

Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models

Published on: April 1, 2022

4.8K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Locally advanced breast cancer often requires neoadjuvant chemotherapy for tumor downstaging.
  • Conventional regimens can be associated with significant toxicity.
  • Pathological complete response (pCR) is a key indicator of favorable prognosis.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of a novel, less toxic sequential preoperative chemotherapy regimen for locally advanced breast cancer.
  • To assess the impact of concurrent bevacizumab on treatment outcomes.

Main Methods:

  • 32 patients with locally advanced breast cancer received sequential liposomal doxorubicin, paclitaxel, and cyclophosphamide intravenously every 2 weeks.
  • Concurrent bevacizumab was administered without growth factor support.
  • Toxicity, tumor response, pCR rates, recurrence-free survival, and overall survival were assessed.

Main Results:

  • No cardiotoxicity or grade 4/5 toxicity was observed during or after treatment.
  • All patients achieved at least a 30% reduction in tumor size.
  • 9 out of 31 patients (29%) achieved pCR.
  • After 7 years, 22 out of 32 patients (69%) remain recurrence-free, and 27 out of 32 (84%) are alive.

Conclusions:

  • The sequential preoperative chemotherapy regimen is effective and significantly less toxic than conventional approaches.
  • Further investigation of this regimen is warranted.
  • Concurrent bevacizumab did not appear to enhance the benefits of this chemotherapy regimen.